Annals of Hepatology

Papers
(The H4-Index of Annals of Hepatology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
IGFBP2: a possible molecular link between liver, heart, and bloodstream during metabolic dysfunction-associated steatotic liver disease842611252
Association of IFNL3 gene rs4803217 with spontaneous clearance of Hepatitis C virus in patients from West Mexico842280240
CLIF-C-ACLF scale to predict mortality in pediatric patients with acute-on-chronic liver failure842019380
Passenger lymphocyte syndrome, an unusual cause of anemia after liver transplantation808585524
Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity78
A multisociety Delphi consensus statement on new fatty liver disease nomenclature73
STAT3: A key regulator in liver fibrosis71
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease68
The liver in times of COVID-19: What hepatologists should know64
Liver disease and outcomes among COVID-19 hospitalized patients – A systematic review and meta-analysis63
Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review61
The effect of coffee consumption on the non-alcoholic fatty liver disease and liver fibrosis: A meta-analysis of 11 epidemiological studies46
Chemotherapy-associated steatohepatitis46
The effect of liver test abnormalities on the prognosis of COVID-1945
Usefulness of neutrophil-to-lymphocyte ratio (NLR) as a prognostic predictor after treatment of hepatocellular carcinoma." Review article45
A systematic review and meta-analysis of the COVID-19 associated liver injury43
Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)42
Osteopontin – A potential biomarker of advanced liver disease42
Clinical treatment of cholangiocarcinoma: an updated comprehensive review39
Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis39
Circ-PRMT5 enhances the proliferation, migration and glycolysis of hepatoma cells by targeting miR-188-5p/HK2 axis34
Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes33
Clinical features and risk factors of COVID-19-associated liver injury and function: A retrospective analysis of 830 cases33
Silymarin is an ally against insulin resistance: A review32
ABCB4 disease: Many faces of one gene deficiency32
Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C31
COVID-19 and the liver: What do we know after six months of the pandemic?29
Standardization of conventional chemoembolization for hepatocellular carcinoma28
0.038763999938965